131 related articles for article (PubMed ID: 35131603)
1. PDIA4 promotes glioblastoma progression via the PI3K/AKT/m-TOR pathway.
Wang M; Zhang W; Liu Y; Ma Z; Xiang W; Wen Y; Zhang D; Li Y; Li Y; Li T; Chen L; Zhou J
Biochem Biophys Res Commun; 2022 Mar; 597():83-90. PubMed ID: 35131603
[TBL] [Abstract][Full Text] [Related]
2. Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy.
Tu Z; Wang C; Hu Q; Tao C; Fang Z; Lin L; Lei K; Luo M; Sheng Y; Long X; Li J; Wu L; Huang K; Zhu X
J Exp Clin Cancer Res; 2023 Mar; 42(1):77. PubMed ID: 36997943
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-378a-3p contributes to ovarian cancer progression through downregulating PDIA4.
Chanjiao Y; Chunyan C; Xiaoxin Q; Youjian H
Immun Inflamm Dis; 2021 Mar; 9(1):108-119. PubMed ID: 33159506
[TBL] [Abstract][Full Text] [Related]
4. RRAGB-mediated suppression of PI3K/AKT exerts anti-cancer role in glioblastoma.
Li Q; Liu X; Mao J; Liu S; Hou B; Li K; Fang D
Biochem Biophys Res Commun; 2023 Oct; 676():149-157. PubMed ID: 37517217
[TBL] [Abstract][Full Text] [Related]
5. LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway.
Ni H; Wang K; Xie P; Zuo J; Liu W; Liu C
Cell Mol Neurobiol; 2021 Jan; 41(1):79-90. PubMed ID: 32236901
[TBL] [Abstract][Full Text] [Related]
6. LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
Zhong C; Chen Y; Tao B; Peng L; Peng T; Yang X; Xia X; Chen L
BMC Cancer; 2018 Jul; 18(1):722. PubMed ID: 29980193
[TBL] [Abstract][Full Text] [Related]
7. Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway.
Cheng Y; Xie P
J Biochem Mol Toxicol; 2019 Nov; 33(11):e22392. PubMed ID: 31503386
[TBL] [Abstract][Full Text] [Related]
8. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
Guan Y; He Y; Lv S; Hou X; Li L; Song J
J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
[TBL] [Abstract][Full Text] [Related]
10. NQO1 drives glioblastoma cell aggressiveness through EMT induction via the PI3K/Akt/mTOR/Snail pathway.
Zheng L; Yang S; Xu R; Yang Y; Quan J; Lin Z; Quan C
Int J Oncol; 2023 Oct; 63(4):. PubMed ID: 37594082
[TBL] [Abstract][Full Text] [Related]
11. Quiescin Sulfhydryl Oxidase 1 Regulates the Proliferation, Migration and Invasion of Human Glioblastoma Cells via PI3K/Akt Pathway.
Geng Y; Xu C; Wang Y; Zhang L
Onco Targets Ther; 2020; 13():5721-5729. PubMed ID: 32606784
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-6071 Suppresses Glioblastoma Progression Through the Inhibition of PI3K/AKT/mTOR Pathway by Binding to ULBP2.
Zhou Y; An H; Wu G
Onco Targets Ther; 2020; 13():9429-9441. PubMed ID: 33061429
[TBL] [Abstract][Full Text] [Related]
13. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
14. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway.
Tang Q; Cao H; Tong N; Liu Y; Wang W; Zou Y; Xu L; Zeng Z; Xu W; Yin Z; Ma W; Wang Q
Phytomedicine; 2022 May; 99():154016. PubMed ID: 35278900
[TBL] [Abstract][Full Text] [Related]
15. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
Yin F; Huang X; Xuan Y
Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
[TBL] [Abstract][Full Text] [Related]
16. POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway.
Yang R; Wang M; Zhang G; Li Y; Wang L; Cui H
Cell Death Dis; 2021 Apr; 12(5):433. PubMed ID: 33931589
[TBL] [Abstract][Full Text] [Related]
17. Voxtalisib and low intensity pulsed ultrasound combinatorial effect on glioblastoma multiforme cancer stem cells via PI3K/AKT/mTOR.
Tutak I; Ozdil B; Uysal A
Pathol Res Pract; 2022 Nov; 239():154145. PubMed ID: 36240647
[TBL] [Abstract][Full Text] [Related]
18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
19. Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway.
Kuo TF; Chen TY; Jiang ST; Chen KW; Chiang YM; Hsu YJ; Liu YJ; Chen HM; Yokoyama KK; Tsai KC; Yeh HH; Chen YR; Yang MT; Yang CY; Yang WC
Oncogene; 2017 Sep; 36(39):5484-5496. PubMed ID: 28534513
[TBL] [Abstract][Full Text] [Related]
20. Protein disulfide isomerase family member 4 promotes triple-negative breast cancer tumorigenesis and radiotherapy resistance through JNK pathway.
Tao J; Xue C; Cao M; Ye J; Sun Y; Chen H; Guan Y; Zhang W; Zhang W; Yao Y
Breast Cancer Res; 2024 Jan; 26(1):1. PubMed ID: 38167446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
